The SGLT2 inhibitor empagliflozin reduced the risk of the primary endpoint, HF hospitalization and renal outcomes independently of baseline SBP, in patients with HFrEF in the EMPEROR-Reduced trial.
Reduction of CV and renal outcomes by empagliflozin in HFrEF patients in the EMPEROR-Reduced trial was independent of baseline NT-proBNP levels. Empagliflozin reduced NT-proBNP levels, which was associated with a reduction in adverse outcomes.
EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.
EASD 2021 In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.
ESC 2021 FIDELITY was a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, which showed that finerenone reduced the risk of CV and renal outcomes in patients with T2DM and mild-to-severe CKD.
ESC 2021 Kevin Damman discusses the results of the FIGARO-DKD trial which compared the nonsteroidal MRA finerenone with placebo in patients with diabetes and chronic kidney disease.
ESC 2021 The FIGARO-DKD trial showed that the nonsteroidal MRA finerenone significantly reduced the risk of CV outcomes in patients with mild-to-moderate kidney disease and diabetes.
ESC 2021 EMPEROR-Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, compared to placebo, reduced HF hospitalizations by ~30% in patients with HF across a range of LVEF from <25% to <65%.
Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.
This study showed that prescription rates of evidence-based medical therapies are suboptimal in patients with comorbid HFrEF and CKD, even at eGFR levels where therapies are not contraindicated by kidney dysfunction.
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.
This analysis of the PIVOTAL trial showed that treatment with high-dose IV iron administered proactively, compared to low-dose IV iron administered reactively, decreased the occurrence of first and recurrent HF events in patients receiving hemodialysis.